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Abstract
Modifications to work and work ability assessment are required to prevent occupational 
transmission of hepatitis C virus (HCV). This is usually required in the health care setting, 
where exposure-prone procedures (EPPs) should not be carried out by infectious carriers 
of HCV. The risk of an individual surgeon acquiring HCV has been estimated at 0.001–
0.032% per annum. Even in an area with a high prevalence of HCV among its population, 
the risk of acquiring HCV through occupational exposure is low. Rates of viral clearance 
with treatment of acute HCV infection are considerably higher than treatment of chronic 
HCV infection. Consequently, it is imperative that health care workers follow universal 
precautions and promptly report all exposures to blood or body fluid exposures accord-
ing to their local policy. Health care workers who embark on, or transfer to, a career 
that requires EPP (exposure-prone procedures and dialysis work) should be assessed to 
ensure that they are free from infection with HCV. If the HCV antibodies are positive, the 
health care worker should be tested for HCV RNA PCR. If the HCV RNA PCR is negative 
on two separate occasions, the health care worker may be permitted to perform EPPs. If 
the HCV RNA PCR is positive, the health care worker should not be allowed to perform 
EPPs. Health care workers who already perform EPPs and who believe they may have 
been exposed to HCV infection should be advised to seek advice from their occupational 
health department for confidential advice on whether they should be tested.
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1. Introduction
Work ability assessment or fitness to work refers to the process of ensuring that an employee 
can complete a task safely without presenting a risk to themselves, their colleagues, the com-
pany, or a third party. This term also refers to the impact of sickness and absence of employ-
ees in order to assess the possibility of having an employee return to work quickly and safely. 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
Work ability assessments are most often performed to determine medical fitness after an ill-
ness or injury, sometimes at the request of an employer after an offer of employment or as a 
condition of a job transfer.
Fitness to work assesses the capacity of an individual to perform physical and psychologi-
cal work tasks according to the demands of the job. This demand may be directly associated 
with a task (e.g., carrying loads) or may be associated with a location that will impact the 
individual’s health. Therefore, fitness to work addresses both the task and the location of the 
work to be done.
Reduced work productivity (WP) is a measure of the impact of illness and treatment burden in 
patients diagnosed with chronic diseases [1]. Patient’s WP in the setting of a chronic condition 
presents a complex phenomenon that cannot be understood only by obtaining patient’s clini-
cal information. It is also important to collect patient-reported outcomes, especially ones that 
capture patients’ energy and physical components. Hepatitis C (HCV) infection has a consid-
erable negative impact on patient-reported outcomes (PRO) and patients’ WP [2]. Numerous 
manifestations of HCV lead to an economic burden related to the complications and extrahe-
patic manifestation, thus decreasing WP [3]. For that reason, it is important to collect infor-
mation that can help caregivers to develop a plan for maintaining patients’ employment. 
Targeting important aspects of PROs has a substantial positive impact on patients’ well-being 
as well as their WP, which results in notable economic benefits for the whole society [4].
2. Impact of HCV infection on work ability and productivity
Chronic HCV is a global health problem affecting 130–170 million people worldwide (80% of 
patients with acute HCV infections will develop chronic HCV). Every year, 3–4 million people 
are infected, and approximately 9 million patients have HCV infection in Europe, with greater 
prevalence in the southern and eastern European regions [5]. Around 2.7–4.1 million people 
have chronic HCV (HCV) in the United States. While frequently believed of as an asymptom-
atic disease, numerous studies have shown that those with chronic HCV experience increased 
work impairment revealed as decreased WP and increased absenteeism and presenteeism 
(attending work while being impaired) [6]. Risk factors identified included blood transfusion, 
injection drug use, employment in patient care or clinical laboratory work, exposure to a sex 
partner or household member who has had a history of hepatitis, exposure to multiple sex 
partners, and low socioeconomic level. These studies reported no association with military 
service or exposures resulting from medical, surgical, or dental procedures, tattooing, acu-
puncture, ear piercing, or foreign travel. If transmission from such exposures does occur, the 
frequency might be too low to detect [7].
Working in the health care, emergency medical (e.g., emergency medical technicians and para-
medics), and public safety sectors (e.g., fire-service, law-enforcement, and correctional facility 
personnel) who have exposure to blood in the workplace are at high risk for being infected 
with bloodborne pathogens. Nevertheless, occurrence of HCV infection among health-care 
workers, including surgeons, is no greater than the general population, averaging 1–2%, and 
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is 10 times lower than that for HBV infection [8]. In a single study that evaluated risk factors 
for infection, a history of unintentional needle-stick injury was the only occupational risk fac-
tor independently associated with HCV infection [9].
Among health care workers, the prevalence of HCV infection is about the same as that of the 
general population: 1.5%. Following percutaneous exposure of health care workers to infected 
blood, the risk of HCV seroconversion ranges from 0 to 10%, with an average of 1.8% [7].
HCV infection is a major cause of fatigue, muscle and joint pain, depression, and other psy-
chological disorders, which decrease patient health-related quality of life (HRQL) and health 
utility [10]. Patients with chronic HCV infection demonstrated lower HRQL compared with 
the general population. Recently, investigators have turned their interest to the impact of 
HCV infection on absenteeism, work force participation, and overall work impairment.
Even if patients are employed, the complete participation productivity may be limited. 
Worker productivity is measured through two key concepts: presenteeism and absenteeism. 
Absenteeism is related to the percentage of work time missed, while presenteeism is related 
to the percentage of impairment experienced at work time missed because of one’s health [6].
To date, numerous studies have demonstrated the impact of HCV on health care costs. 
Previous studies have evaluated health care costs associated with HCV to be $2470 per patient 
during the period from 1997 to 1999 [11, 12]. However, direct medical costs present only 
part of the societal burden of HCV infection. On the other hand, indirect costs related to 
work impairment have been ignored in the HCV literature for a long time. Previous models 
have omitted work impairment completely [13] or have evaluated productivity losses only in 
the premature mortality and disability as a consequence of projected late stage liver disease. 
Direct costs associated with HCV are fundamental. Also, indirect economic and humanistic 
costs are major and arise from the reduction of HRQL owing to both the disease and HCV 
treatments; this is related on the patient work, daily activities, and lifestyle [14].
Recent investigation has recognized a significant burden of HCV infection on work produc-
tivity, with infected patients missing 9% of working hours in the working week and report-
ing an average of 27% impairment while at work. Also, database study reported that HCV 
patients were 7.5% less productive based on work units per hour [15].
For better understanding of the societal impact of HCV, the association between the virus 
and work force participation and WP loss must be observed. It is also essential to investi-
gate potential confusing variables that may contribute to a relationship between HCV and 
workplace activity. Nowadays, different studies have reviewed the impact comorbidities, and 
health behaviors may have on health outcomes among HCV patients, including psychiatric 
illness, fibrosis, fatigue, and depressive symptoms [16].
It would be educative and significant for some employers with a short-term focus to uti-
lize a time series approach to document WP changes pre and post-HCV diagnosis. Although 
using a regression approach and a propensity scoring approach ensured a numerous series of 
results, other methodologies may be significant, especially when evaluating economic costs 
associated with HCV [16].
HCV and Work Ability Assessment
http://dx.doi.org/10.5772/intechopen.70774
149
Patients with HCV infection have reduced WP, in terms of both presenteeism (impairment in 
WP while working) and absenteeism (productivity loss due to absence from work). The most 
important drivers of WP in HCV are impairment of physical aspects of PROs and clinical 
history of depression, anxiety, fatigue, and cirrhosis [4]. Some authors emphasize the impact 
of eradicating HCV virus on the WP of chronic HCV (CH-C) patients. Sensitivity analyses 
assessed the possibility that CH-C patients’ labor costs were lower than the general populations 
and presented results by fibrosis stage. Before initiation of treatment, EU patients with CH-C 
genotype 1 (GT1) exhibited absenteeism and presenteeism impairments of 3.54 and 9.12%, 
respectively [17]. About 91.8% of EU patients in the ION trials achieved SVR and improved 
absenteeism and presenteeism impairments by 16.3 and 19.5%, respectively. Weighted aver-
age per-employed patient gains from treatment are projected to be higher in cirrhotic than in 
noncirrhotic patients. CH-C results in a significant economic burden to European society. Due 
to improvements in WP, sustained virologic response with treatment could provide substan-
tial economic gains, partly offsetting the direct costs related to its widespread use [17].
HCV infection is generally considered an asymptomatic disease. However, studies have 
shown that HCV has a substantial negative impact on patients’ quality of life and function-
ing. Su et al. [15] evaluated a total number of near 340,000 subjects. Workers with HCV had 
significantly more lost workdays per worker compared to the control cohort, including sick 
leave, short-term disability, and long-term disability. HCV-infected workers had 4.15 more 
days of absence per worker compared to the control cohort. Efficiency was measured by units 
of work processed per hour and workers with HCV processed 7.5% fewer units per hour than 
employees without HCV. All health care costs among HCV workers were significantly higher 
compared to the same costs among workers without HCV. This study provides evidence that 
there is a considerable secondary burden of disease and labels an association between HCV 
infection, efficiency, increased absenteeism, and higher health care benefit costs [15].
Gifford et al. [18] showed that at least 50% of the men had symptoms of HCV infection. 
Tiredness was the most common symptom, followed by nausea and pain in the liver. Men 
ignored symptoms of disease in higher percentage compared women. Thirty-five percent of 
men rated their health as ‘fair’ or ‘poor’ compared to 18% of men in the general population. 
Many were concerned about their ability to work and financial income, and more than half 
were worried about being unable to have a drink with their friends. Coughlan et al. presented 
a Dublin study documenting psychological well-being, mental health, and quality of life in 
93 women diagnosed with medically acquired HCV infection. Overall, the women had signifi-
cantly lower quality of life than the healthy female population. No significant difference was 
found between women who had a past or current HCV virus infection; they reported having 
low energy, poor health, and problems with work and other daily activities. Reduced quality of 
life can be related to the diagnostic process rather than HCV infection as such. While HCV have 
a significant physiological effect on the quality of life, it is imperative not to undervalue the 
social and psychological costs of being identified with a stigmatized chronic disease that has an 
unknown progression and outcome [19]. Gill et al. found that HCV compared to divorce, loss 
of source of income, or a move to another city diagnosis is a way more stressful. The authors 
suggested that pre-and post-test counseling and psychosocial support could help to decrease 
the stress related with HCV diagnosis [20]. HCV infection has a significant influence on the 
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quality of life. Not only do symptoms such as fatigue lessen effective functioning but also liv-
ing with a chronic stigmatized disease with an indeterminate future creates problems around 
expose, retrieving care, and satisfying confidence, employment, and relations.
3. The impact of the HCV antiviral therapy on work ability
A patient’s ability to tolerate and adhere to HCV treatment has an impact to WP during the 
course of HCV treatment. This is important concern for patients considering treatment initia-
tion because they will have to deal with the possibility of temporary reduced work participa-
tion during treatment [17].
Eradication of HCV may improve many different components of PRO, including HRQL and 
WP [21]. It is important that evaluation of new regimens for treatment of chronic hepatitis C 
(CHC) includes not only efficacy and safety reports but also data related to important PROs 
such as fatigue, HRQL, and WP [14]. The dual function of PRO is to represent patient experi-
ence with treatment and assess the indirect cost of treatment related to lower WP [22].
Treatment of HCV infection with the combination of peginterferon plus ribavirin (pegIFN/
RBV) is a process with significant and sometimes dose-limiting adverse events. Those adverse 
effects further exacerbate the patient’s already compromised productivity and consequently 
increase economic burden [17]. Brook et al. found that patients who received pegIFN/RBV 
took more sick leave, more long-term disability, and more workers’ compensation than those 
without HCV treatment [3]. Perillo et al. designed a randomized control study and found 
that during treatment with peginterferon-alpha 2a, patients showed less impairment across 
all measures of work functioning and productivity when compared to patients who were 
treated with combination of interferon-alpha 2b plus ribavirin [23]. In a study conducted 
by McHutchison et al., randomly assigned patients who responded to therapy of IFN/RBV 
showed improvements across all measures of work functioning and productivity, in contrast 
with patients who received placebo. In addition, sustained responders work functioning and 
productivity decreased temporarily in approximately 46% of patients [14]. Patients who do 
not achieve an SVR are more likely to miss work or other commitments due to HCV infec-
tion or its treatment than those who achieve SVR. Aggrawal et al. confirmed that employed 
patients with genotype 1 chronic HCV infection receiving treatment have reduced work hours 
and reduced WP levels due to hepatitis or its treatment. This decline was observed early dur-
ing the course of treatment, with return to baseline levels by week 72 post-treatment initia-
tion, suggesting that WP losses can be considered a short-term outcome of HCV treatment [1].
To improve the tolerability and efficacy profile of anti-HCV treatment, a number of inter-
feron-free regimens, such as sofosbuvir, have been developed. In a study by Younossi et al., 
subjects treated with the interferon-free regimen completely recovered by the end of 12 weeks 
of follow-up, their PRO scores returned to baseline values and showed further improvement. 
The impact on WP, especially presenteeism, was significantly more profound with the inter-
feron-containing regimen than with the interferon-free regimen. Also, subjects who received 
the interferon-free regimen experienced substantially less fatigue compared with the subjects 
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receiving interferon-containing regimens [22]. Another study by Younossi et al. showed that 
interferon and ribavirin-free regimen are associated with significant gains in most aspects of 
HRQL during treatment regardless of the stage of liver disease [24]. Expanding the access to 
a highly effective cure for all HCV-infected patients will improve the clinical outcomes but 
also patient-reported outcomes such as HRQL and work productivity, resulting in a superb 
comprehensive benefit to patients and society.
In conclusion, successful treatment and achieving SVR regardless of therapy have been asso-
ciated with better economic outcomes [25]. For that reason, there is a strong evidence that this 
improvement can positively impact the indirect economic burden of HCV by improving WP.
4. Conclusions
In general, work-related activities should not pose a risk to patient with chronic liver disease 
[26]. The exception would be:
1. Patients with hepatic encephalopathy for whom certain task such as driving and operating 
heavy machinery may be risky due to impaired judgment and cognitive defects.
2. Working with hepatotoxic chemical such as carbon tetrachloride, vinyl chloride, and poly-
chlorinated biphenyls (PCBs).
Patients with advanced liver disease have decreased exercise capacity from anemia, ascites, 
renal failure, or hepato-pulmonary syndrome, and work limitations are advised [26].
Modifications to work and work ability assessment are required to prevent occupational 
transmission of HCV. This is usually only required in the health care setting, where infec-
tious carriers of HCV should not carry out exposure-prone procedures (EPP). Even in 
an area with a high prevalence of HCV among its population, the risk of acquiring HCV 
through occupational exposure is low—the risk of an individual surgeon acquiring the HCV 
has been estimated at 0.001–0.032% per annum [26, 27]. Rates of viral clearance with treat-
ment of acute HCV infection are considerably higher than treatment of chronic HCV infec-
tion. Consequently, it is imperative that health care workers follow universal precaution and 
promptly report all exposures to blood or body fluid exposures according to their local policy.
Health care workers who embark on, or transfer to, a career that requires EPP (exposure-
prone procedures and dialysis work) should be assessed to ensure that they are free from 
infection with HCV. Members of staff known to have been exposed to the blood of a HCV-
positive patient through sharps injury should continue to work normally, but it is necessary 
to do the following procedure [26] that is also shown at Figure 1:
1. HCV RNA polymerase chain reaction test 6 weeks after exposure.
2. Twelve weeks after exposure, HCV RNA polymerase chain reaction test should be taken 
again, together with HCV antibody testing.
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3. Six months after exposure, additional HCV antibody testing should be commenced (re-
peated negative testing designates infection absence).
Those who have positive test results should stop undertaking EPPs instantly and should be 
taken as soon as possible for specialist assessment by a gastroenterologist and/or infectologist. 
Health care workers who already perform EPPs and who believe they may have been exposed 
to HCV infection should be advised to seek advice from their occupational health department 
for confidential advice on whether they should be tested.
Figure 1. Investigation of HCV status in a worker performing exposure-prone procedures (Modified after Palmer et al. [26]).
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Those health care workers who had HCV infection and have been treated with antiviral treat-
ment may return to EPPs if they have tested negative to HCV RNA for at least 6 months after 
cessation of treatment. They should have one additional check for HCV RNA 6 months later. 
Present standard laboratory tests cannot demonstrate complete clearance of virus but can state 
that the virus is undetectable. In these situations, infectivity is likely to be so low that it is safe 
to return to EPPs and reactivation of infection is unlikely so no further testing is required. There 
is indication that infection remains within hepatocytes and can be reactivated following treat-
ment with monoclonal antibodies (such as Rituximab) and other immunosuppressants (such 
as TNF-α inhibitors) including cancer chemotherapy. Recent data suggest that rituximab-based 
chemotherapy increases HCV expression in hepatic cells, can become a mark for a cell- mediated 
immune response after the treatment removal and the renewal of the immune control. Some 
studies have examined the incidence of HCV reactivation and related hepatic flare in patients 
with oncohematological diseases receiving R-CHOP (rituximab, cyclophosphamide, doxorubi-
cin, vincristine, and prednisone). These studies suggest that the hepatic flares are often asymp-
tomatic, but life-threatening liver failure occurs in closely 10% of cases [28].
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